Introduction: The emergency of Mycobacterium tuberculosis resistant to the first line drug reduced access possibility to second line drugs for appropriate treatment and required for urgent action especially in le Democratic Republic of Congo (DRC), which counts among the highest tuberculosis (TB) burden countries in Africa. Objective: To present prevalence and describe multidrugresistant tuberculosis cases in North-Kivu Province identified by using Genexpert technology. Methods: We conducted an observational prospective study on multidrug-resistant tuberculosis (MDR-TB) cases in North-Kivu Province, DRC from 2017 to 2018. All cases of MDR-TB identified by Genexpert MTB/ RIB were included in this series. Result: Of 15,544 tuberculosis cases registered during the study period, 19 cases of MDR-TB were identified. 57.9% was male, 89.5% was retreatment cases and 5.3% was coinfection HIV/TB cases. Conclusion: This new molecular technology diagnostic facilitates multidrug-resistance tuberculosis detection and improves the reporting of data lack.
Introduction
Tuberculosis is the common causes of infectious disease related morbidity and mortality worldwide [1] . Multidrug-resistant tuberculosis (MDR-TB) defined as a disease caused by Mycobacterium tuberculosis resistant to at least isoniazid and rifampicin is an emergency problem in many part of world [2] [3] . The emergency of Mycobacterium tuberculosis resistant to the first line drug [6] [7] [8] limited access to second line drugs for appropriate treatment and called for urgent action [9] [10] . Drug resistant TB patients require prolonged treatment using second line medication that are less effective and more toxic [5] [11] [12] [13] [14] [15] . The acquisition of Mycobacterium tuberculosis resistance may be occurring from using of inferior regimens, poor adherence to anti-TB drug, chronic malnutrition and co-infection to HIV/TB. This study, aims to present prevalence and describe multidrug-resistant tuberculosis cases in North-Kivu Province identified by using Genexpert technology. Table 1 shows that 19 cases of MDR-TB identified by Genexpert Assay. 
Material and Methods

Finding
Discussion
The Democratic Republic of Congo National Tuberculosis and Leprosy Program (NTLP) in 2013, progressively introduced the GeneXpert MTB/ RIF technology in the provincial laboratories, mainly motivated by the lack of data on MDR TB incidence.
The World Health Organization recommends this assay as a first-line diagnostic test for persons with suspected pulmonary TB who are considered to be at risk for harboring MDR TB bacilli [24] .
The trend of national prevalence of multidrug resistance tuberculosis disease observed in DRC ( Figure 1 ); it's could be explained by introduction of using GeneXpert MTB/RIF in this country. In light of National prevalence and provincial tuberculosis frequency, this new molecular technology diagnostic, facilitates multidrug-resistance tuberculosis detection and improves the reporting of data lack [25] .
However, Genexpert MTB/RIF number in the Nord-Kivu Province is very insufficient and could explained the low frequency case of multidrug-resistant tuberculosis reported in our study (Table 1) . However, this study has the merit of reported for the first time MDR-TB in the Province. Also, some authors [26] , reported that utilization of Genexpert MTB/RIF increasing the number of tuberculosis patients Partners contribution) . The prevalence of MDR-TB in this study was 122 cases per 100,000 populations. This prevalence is largest burden compared to DRC national prevalence in 2017 (Figure 1 ) and to Kwazulu-Natal MDR-TB prevalence in South-Africa [27] . This prevalence we reported represent an important proportion of all MDR-TB patient in Democratic Republic of Congo which have 26 Provinces. However, could be lower because of insufficient number of Genexpert Assay in the North-Kivu Province especially in rural area.
In our series, more cases of Multidrug-resistant were notified by Mweso and Karisimbi health zone, which zone had molecular diagnostic test (Figure 2 ). This result showed the interest to switched and screening tuberculosis with new molecular technology. It's urgent to carried more Genexpert in North-Kivu Province in aims to detected more cases of Multidrug-resistant tuberculosis. Others authors, in Mbuji-Mayi [24] and in Bukavu [25] reported the same observation. In our site study, it's could be very interesting to have one Genexpert MTB/RIF in each health zone in North-Kivu Province if we wanted to according care of quality to patient with tuberculosis.
Our study found that majority of patient (79%) were adult, average age was 28.8 years old and extremes ages were 7 -53 years. Other authors found similar [26] . However, the rate of pediatric tuberculosis is indicator key for recent transmission and present reservoir for diseases in the community. In our series, the children tuberculosis rate was 21.0%, this low rate detection could be explained in our context by difficulties to collected sputum smear and gastric fluid for culture, drug susceptibility testing. May also by explain, to poor tuberculosis control in adult group, poor anti-tuberculosis vaccination status in children, chronic malnutrition and poverty caused by war, rebellion and arms conflicts repetition in this party of Democratic republic of Congo. Some authors [28] [29] identified similar observation. So, pediatric tuberculosis can be controlled or cared if timely and appropriate treatment is completed.
Male represent 57.9% of the study and sex ratio was 1.4. Aznar et al. [30] reported similar result. But in this study, we didn't find explication for this difference based on genre in all revised literatures.
Most of patient (89.5%) was retreatment cases. Interrupted tuberculosis treatments pose a public health challenge because it permits the development of tuberculosis drug-resistant. In our study, this could be due to poor adherence to tuberculosis drug, consumption alcohol which induce amnesia and forget take tuberculosis drug, geographic inaccessibility, insecurity in majority of health zone of this party of Democratic Republic of Congo. Some patients lived more than 40 km away from the treatment centers. Other authors [31] [32], reported that poverty is also an important factor influencing tuberculosis treatment's interruption. In North-Kivu Province patients paid the chest x-rays control out their pockets, this is a big problem for some vulnerable people in this party.
HIV/Tuberculosis coinfection, is the leading causes of mortality in several African Sub-Saharan countries. In our study prevalence of HIV was 5.1% and 10.5% of patients dead. This prevalence of HIV in our series is the same with Yifeng Lu HIV prevalence observed in Bukavu [25] , so lower than the HIV-TB coinfection rate reported in Lesotho [33] , Nigeria [34] , Tanzania [35] and Cape Town [36] . In North-Kivu context, HIV status could be caused by sexual violence, unprotected and early sexually acquired.
Conclusion
This study shows that Genexpert technology is necessary to identify and improve the reporting of MDR-TB cases; 19 cases of MDR-TB were identified in North Kivu Province during the period studied. Most of MDR-TB patients were retreatment cases. We recommend using of this molecular technology in all 34 Health zones in the Nord-Kivu Province in order to improve the screening community MDR-TB cases.
